TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study

Hepatology International 2026

View at publisher
Authors: Xuegang Yang, Li-Wei Deng, Yong Zhao, Bo Peng, Bin Liu, Shi-Feng Feng, Dongxu Liu, Jun-Feng Liu, Yan-Yuan Sun, Yan Chen, Changli Liao, Chi Zhang
+5 more Le Liu, Lei Cao, Yi Ren, Guo wei, Guo-Hui Xu
DOI: 10.1007/s12072-026-11052-0
Cited by: 4
References: 25

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Hepatology International
Publisher
Springer Science and Business Media LLC
Volume
20
Issue
2
Pages
384–395
Publication date
17 February 2026
Language
EN